Sucampo Pharmaceuticals, Inc. is a pharmaceutical Company. The Company is focused on the discovery, development and commercialization of drugs based on prostones. It is focused on developing prostones to treat gastrointestinal, ophthalmologic, CNS, vascular, and respiratory diseases as well as other potential therapeutic applications. To date, two prostone products have received marketing approval, AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl). During the year ended December 31, 2011, third prostone, cobiprostone, has been studied in phase II trials in humans; two other prostones have also been developed for human testing, SPI 017 and SPI 3608. On March 22, 2011, it entered into a license agreement with R-Tech for unoprostone isopropyl. On July 8, 2011, it obtained the development and commercial rights to a peptide compound from CuroNZ, a New Zealand company. On September 8, 2011, it entered into a research and development collaboration with Numab AG, Switzerland.